Aktienanalyse zu Pacira Biosciences Inc (PCRX)PCRXPacira Biosciences Inc

Pacira BioSciences, Inc. is the holding company for its subsidiary, Pacira Pharmaceuticals, Inc. The Company has three commercial-stage non-opioid treatments: EXPAREL (bupivacaine liposome injectable suspension), a long-acting local analgesic approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain, and iovera, a handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The Company is also advancing the development of PCRX-201, a locally administered gene therapy with the potential to treat largely prevalent diseases like osteoarthritis. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Pacira Biosciences Inc is a good buy right now, trading at $25.76 with a forward P/E of 9.42, indicating potential for growth compared to its earnings. The recent Q2 earnings report showed a non-GAAP EPS of $0.75, beating expectations by $0.10, and total revenue of $192.4 million, a 6.2% year-over-year increase. However, insider selling has increased by 636.27%, which is a notable risk.

16 analysts cover PCRX: 10 rate it Buy, 5 Hold and 1 Sell. The average price target is 30.33.